UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
July 10, 2024

SANUWAVE Health, Inc.
(Exact name of registrant as specified in its charter)

Nevada
000-52985
20-1176000
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

11495 Valley View Road, Eden Prairie, Minnesota
  
55344
(Address of principal executive offices)
  
(Zip Code)

Registrant’s telephone number, including area code
(952) 656-1029

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
N/A
N/A
N/A

Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.

On July 10, 2024, Sanuwave Health, Inc., a Nevada corporation (the “Company”), issued a press release announcing certain preliminary financial results for the quarter ended June 30, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01
Financial Statements and Exhibits.

(d)
Exhibits.

Exhibit No.
  
Description
     
 
Press release dated July 10, 2024
104
  
Cover Page Interactive Data File––the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
SANUWAVE HEALTH, INC.
  



 
Dated: July 10, 2024 By: /s/ Peter Sorensen  
 
Name:
Peter Sorensen
  
 
Title:
Chief Financial Officer
  


Exhibit 99.1


SANUWAVE Health Announces Preliminary Revenue Results for the Second Quarter 2024 (Ended June 30, 2024)

SANUWAVE is pleased to announce preliminary revenues of $7.0 million to $7.2 million for the second quarter ended June 30, 2024.  This represents the highest quarterly revenues in company history.
 
Q1 2024 revenue increased between 50% and 54% compared to Q2 2023.
 
UltraMist revenues for Q2 2024 increased by more than 60% versus Q2 2023 and accounted for approximately 97% of the Company’s total revenues.
 
UltraMist applicator sales were an all time quarterly record and were approximately 65% of total revenues.
 
EDEN PRAIRIE, MN, July 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- SANUWAVE Health, Inc. (the "Company" or "SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the second quarter of 2024 are expected to be in the range of $7.0 to $7.2 million, an increase of 50% to 54% over Q2 2023 and consistent with the upper end of the range of guidance given in the Company’s Q1 2024 earnings release from May 10, 2024.
 
“Sanuwave is pleased to announce an all time record revenue quarter and our second consecutive quarter of greater than 50% year on year revenue growth,” said CEO Morgan Frank.  “We’re particularly excited to report over 60% growth in our core UltraMIST business and that our consumable business remains so strong.  We remain committed to our plan of rapid growth, operating profitability, and to become a premier franchise in the wound care space.  The Company plans to release its full Q2 results in mid-August, and we look forward to speaking with you then to give you a more complete update on our quarterly performance and our future plans and guidance.”
 
The preliminary revenue results described herein are based on management’s initial analysis of the second quarter ended June 30, 2024, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
 
About SANUWAVE
 
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
 
SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
 
Forward-Looking Statements
 
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations and constraints, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with supply chain and production constraints, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, the Company’s ability to consummate the proposed business combination with SEP Acquisition Corp. and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
 
Contact: investors@sanuwave.com
 

v3.24.2
Document and Entity Information
Jul. 10, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 10, 2024
Entity File Number 000-52985
Entity Registrant Name SANUWAVE Health, Inc.
Entity Central Index Key 0001417663
Entity Incorporation, State or Country Code NV
Entity Tax Identification Number 20-1176000
Entity Address, Address Line One 11495 Valley View Road
Entity Address, City or Town Eden Prairie
Entity Address, State or Province MN
Entity Address, Postal Zip Code 55344
City Area Code 952
Local Phone Number 656-1029
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
SANUWAVE Health (QB) (USOTC:SNWV)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more SANUWAVE Health (QB) Charts.
SANUWAVE Health (QB) (USOTC:SNWV)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more SANUWAVE Health (QB) Charts.